Clinical Trials · NCT01789957
Extension Study for 2993-112
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 225
- Start date
- Sep 2002
- Locations
- 226 sites, United States, Canada
- Primary endpoint
- Change in HbA1c from Day 1 of Protocol 2993-112 to Week 52 (or termination)